Form 8-K - Current report:
SEC Accession No. 0001651308-22-000013
Filing Date
2022-02-02
Accepted
2022-02-02 16:12:24
Documents
14
Period of Report
2022-01-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20220128.htm   iXBRL 8-K 56015
2 EX-99.1 ax2feb2022xex991xnewdirect.htm EX-99.1 15503
3 EX-99.2 ax2feb2022xex992xbrukinsa1.htm EX-99.2 47636
  Complete submission text file 0001651308-22-000013.txt   283075

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20220128.xsd EX-101.SCH 1996
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20220128_lab.xml EX-101.LAB 25214
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20220128_pre.xml EX-101.PRE 13249
8 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20220128_htm.xml XML 11920
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 22583749
SIC: 2834 Pharmaceutical Preparations